2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112248
    (Rac)-HAMI 3379 712313-35-4
    (Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT2) receptor antagonist.
    (Rac)-HAMI 3379
  • HY-112294
    TIE-2/VEGFR-2 kinase-IN-1 453590-24-4 99.91%
    TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-1
  • HY-112678
    TM6008 945008-17-3 99.51%
    TM6008 is a potent and orally active prolyl hydroxylase (PHD) inhibitor. TM6008 chelats transition metal (copper) and inhibits the autoxidation of ascorbic acid with an IC50 value is 0.57 μM. TM6008  exerts organ protection against ischemia in vivo and can be used for cerebrovascular disease research.
    TM6008
  • HY-113071
    Mevalonic acid 150-97-0 ≥99.0%
    Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure.
    Mevalonic acid
  • HY-113495
    Deoxypyridinoline 83462-55-9
    Deoxypyridinoline is an endogenous metabolite present in Urine that can be used for the research of Heart Failure.
    Deoxypyridinoline
  • HY-113673
    A-935142 1031335-85-9 98.77%
    A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization.
    A-935142
  • HY-113986
    Dexfadrostat 102676-87-9 98.75%
    Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor. Dexfadrostat also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats..
    Dexfadrostat
  • HY-114161
    H-Val-Pro-Pro-OH 58872-39-2 99.86%
    H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
    H-Val-Pro-Pro-OH
  • HY-114275
    Justicidin B 17951-19-8 ≥99.0%
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation.
    Justicidin B
  • HY-114671
    Taprostene 108945-35-3 98%
    Taprostene (CG-4203) is a synthetic, chemically stable analogue of Prostacyclin (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects.
    Taprostene
  • HY-114866
    Eritadenine 23918-98-1
    Eritadenine (Lentinacin) is a S-adenosyl-L-homocysteine hydrolase (SAHH) inhibitor. Eritadenine can be found in secondary metabolites of shiitake mushrooms. Eritadenine lowers blood cholesterol levels and can be used in cardiovascular disease research.
    Eritadenine
  • HY-115745
    Calmodulin antagonist-1 78957-84-3 ≥98.0%
    Calmodulin antagonist-1 (A-5) is a calmodulin (CaM) antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca2+-phosphodiesterase (PDE) (IC50=66 μM). Calmodulin antagonist-1 also inhibits trypsin-treated Ca2+-PDE (IC50=560 μM) in a competitive fashion with respect to cyclic GMP.
    Calmodulin antagonist-1
  • HY-116028
    15-deoxy-Δ12,14-Prostaglandin D2 85235-11-6 ≥98.0%
    15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of prostaglandin receptor 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC50=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC50=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC50=320 ng/mL).
    15-deoxy-Δ12,14-Prostaglandin D2
  • HY-116078
    CKD-519 1402796-27-3 99.65%
    CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an IC50 of 2.3 nM.
    CKD-519
  • HY-116111
    AG 370 134036-53-6
    AG 370, an indole tyrphostin, is a potent PDGF-induced mitogenesis inhibotor (IC50 of 20 μM). AG 370 displays weak inhibition of the EGF receptor.
    AG 370
  • HY-116196
    17-HETE 128914-47-6 98.2%
    17-HETE is arachidonic acid metabolite through cytochrome P-450 pathways, which consists of 17R-HETE and 17S-HETE enantiomers. 17-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
    17-HETE
  • HY-117724
    AZ3976 1418747-15-5 98.03%
    AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC50 value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC50 of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay.
    AZ3976
  • HY-118178
    LY43578 26766-35-8 99.76%
    LY43578 is an orally active aromatase inhibitor. LY43578 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 0.3 and 5 μΜ, respectively. LY43578 can be used for neurological disorder study.
    LY43578
  • HY-118543
    TM6089 863421-32-3 99.37%
    TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector.
    TM6089
  • HY-119909
    GNX-865 1223568-82-8 98.09%
    GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo.
    GNX-865
Cat. No. Product Name / Synonyms Application Reactivity